Novo Nordisk issues statement on illegal mass compounding and deceptive advertising by Hims & HersGlobeNewsWire • 02/05/26
Eli Lilly Stock Soars While Novo Nordisk Sinks—Why the Weight-Loss Leaders Are Headed in Opposite DirectionsInvestopedia • 02/04/26
Novo Nordisk Plunges After Releasing a Brutal Forecast. Should You Dump the Stock?The Motley Fool • 02/04/26
Eli Lilly Soars, Novo Nordisk Plummets On GLP/Obesity Updates - Here's What To DoSeeking Alpha • 02/04/26
Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales OutlookZacks Investment Research • 02/04/26
NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 ViewZacks Investment Research • 02/04/26
Novo Nordisk CEO tells investors to expect weight-loss drug pricing to go down before it comes back upMarket Watch • 02/04/26
CNBC Daily Open: UBS posts strong earnings while Novo Nordisk's U.S. shares crater on slowing growthCNBC • 02/04/26